Meeting Coverage
ESMO
European Society for Medical Oncology
Latest ESMO Meeting Coverage
POD1UM-303/InterAACT 2 data also trend in the direction of better overall survival
But combination may be appropriate for shrinking tumors before surgery
Second-line T-DXd best option in patients with and without intracranial activity, experts says
Data support that ICI rechallenge should be discouraged in patients with advanced RCC
Follow-up results from phase II study show 12-month EFS rate of 89% in stage II-IV disease
Time to radiographic progression doubled with 177Lu-PSMA-617
Amivantamab-based regimens improved oncologic outcomes, but with more side effects
Adjuvant alectinib reduces disease-free survival hazard by 76%
Still some unanswered questions about benefit over other drug regimens, expert says
After immunotherapy-TKI failure, belzutifan produces better outcomes versus everolimus
PFS doubled and OS improved, driven by mismatch repair-deficient disease
Tisotumab vedotin reduced risk of death by 30% compared with chemotherapy
Standard dose of sotorasib plus panitumumab reduced risk of progression by 51% vs standard care
Adding amivantamab to chemotherapy improved PFS, induced more rapid and durable responses
Latest Oncology/Hematology Meeting Coverage
-
ASTRO: American Society for Radiation Oncology
September 2024
-
ESMO: European Society for Medical Oncology
September 2024
-
ASCO: American Society of Clinical Oncology
May 2024
-
AACR: American Association for Cancer Research
April 2024